Australian reproductive biotechnology company Memphasys Limited (ASX:MEM) is expanding international sales activity for its Felix sperm preparation system. Its September 2026 quarterly report, released in October, records higher invoicing, new distribution agreements and further regulatory approvals. Alongside this commercial activity, the company received additional …
Imagion Biosystems Limited (ASX:IBX) is a clinical-stage medical imaging company developing MagSense, a nanoparticle-based technology intended to identify cancer-associated molecular targets using magnetic resonance imaging (MRI). Its September 2026 update centres on preparations to begin a US clinical trial in HER2-positive breast cancer, with …
Radiopharm Theranostics Limited (ASX:RAD) is an Australian clinical-stage developer of radiopharmaceutical products intended for cancer imaging and treatment. Recent attention has centred on its RAD101 brain metastases imaging program after an October meeting with the US Food and Drug Administration (FDA), while its latest …
Invion Limited (ASX:IVX) is an Australian biotechnology company developing photodynamic therapy applications based on its Photosoft platform. Its FY26 report documents research expenditure, limited commercial revenue and continuing losses, while recent disclosures describe financing arrangements and collaborations intended to support clinical development. Shares were …
CONNEQT Health Limited (ASX:CQT) develops cardiovascular monitoring devices and related digital services for consumers, healthcare providers and researchers. The company’s FY26 results show increased sales from its arterial health technology, alongside continuing operating losses and a need to manage funding. Its recent US distribution …
At the time of writing this article on 19 October 2026, ReNerve shares were trading at AUD 0.084, up 9.09% during today's trading session. This is a market snapshot rather than a measure of clinical or commercial performance.
Identifai focuses on non-invasive prenatal screening using genetic material obtained from a maternal blood sample. Its Windrose platform is being developed to examine genetic conditions through genome-wide sequencing and machine-learning analysis. The company describes a workflow that combines cell-free DNA sequencing with its analytical …
Microba Life Sciences Limited (ASX:MAP), an Australian microbiome diagnostics and therapeutics business, entered FY27 after reshaping its product range around clinical testing and own-brand supplements. At the time of writing this article on 19 October 2026, its shares were quoted at AUD 0.044, up …
Avecho develops and licenses pharmaceutical delivery technologies built around its proprietary tocopheryl phosphate mixture, known as TPM. Its principal clinical asset is a TPM-enhanced CBD soft-gel formulation under investigation for treating insomnia. The company also identifies applications for its delivery platform in pharmaceutical and …
At the time of writing on 19 October 2026, Syntara shares were trading at AUD 0.020, an increase of 5.26% during the day’s trading session.